152 related articles for article (PubMed ID: 31692672)
41. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
Kuwahara N; Sasaki S; Kobara M; Nakata T; Tatsumi T; Irie H; Narumiya H; Hatta T; Takeda K; Matsubara H; Hushiki S
Int J Cardiol; 2008 Jan; 123(2):84-90. PubMed ID: 17434618
[TBL] [Abstract][Full Text] [Related]
42. The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin.
Baspınar O; Bayram F; Korkmaz S; Aksu M; Kocer D; Dizdar OS; Simsek Y; Toth PP
J Clin Lipidol; 2016; 10(6):1452-1461. PubMed ID: 27919363
[TBL] [Abstract][Full Text] [Related]
43. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Conde K; Pineda G; Newton RS; Fernandez ML
Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
[TBL] [Abstract][Full Text] [Related]
44. The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism.
Krysiak R; Gilowski W; Okopień B
Pharmacol Rep; 2016 Feb; 68(1):196-200. PubMed ID: 26721373
[TBL] [Abstract][Full Text] [Related]
45. Statins inhibit Rho kinase activity in patients with atherosclerosis.
Nohria A; Prsic A; Liu PY; Okamoto R; Creager MA; Selwyn A; Liao JK; Ganz P
Atherosclerosis; 2009 Aug; 205(2):517-21. PubMed ID: 19167712
[TBL] [Abstract][Full Text] [Related]
46. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
Passi S; Stancato A; Aleo E; Dmitrieva A; Littarru GP
Biofactors; 2003; 18(1-4):113-24. PubMed ID: 14695926
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
Kovarik JM; Hartmann S; Hubert M; Berthier S; Schneider W; Rosenkranz B; Rordorf C
J Clin Pharmacol; 2002 Feb; 42(2):222-8. PubMed ID: 11831546
[TBL] [Abstract][Full Text] [Related]
48. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
[TBL] [Abstract][Full Text] [Related]
49. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
50. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
51. Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways.
Lee ST; Chu K; Park JE; Hong NH; Im WS; Kang L; Han Z; Jung KH; Kim MW; Kim M
J Neurochem; 2008 Mar; 104(5):1190-200. PubMed ID: 17976163
[TBL] [Abstract][Full Text] [Related]
52. Effect of itraconazole on the pharmacokinetics of atorvastatin.
Kantola T; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
[TBL] [Abstract][Full Text] [Related]
53. Cholesterol intake and statin use regulate neuronal G protein-gated inwardly rectifying potassium channels.
Bukiya AN; Blank PS; Rosenhouse-Dantsker A
J Lipid Res; 2019 Jan; 60(1):19-29. PubMed ID: 30420402
[TBL] [Abstract][Full Text] [Related]
54. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
Singh S; Willig JH; Mugavero MJ; Crane PK; Harrington RD; Knopp RH; Kosel BW; Saag MS; Kitahata MM; Crane HM
Clin Infect Dis; 2011 Feb; 52(3):387-95. PubMed ID: 21189273
[TBL] [Abstract][Full Text] [Related]
55. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Rakotoniaina Z; Guerard P; Lirussi F; Goirand F; Rochette L; Dumas M; Bardou M
Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):195-206. PubMed ID: 17102939
[TBL] [Abstract][Full Text] [Related]
56. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Krause BR; Newton RS
Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
[TBL] [Abstract][Full Text] [Related]
57. Protective effects of atorvastatin and rosuvastatin on 3,4-methylenedioxymethamphetamine (MDMA)-induced spatial learning and memory impairment.
Eslami SM; Khorshidi L; Ghasemi M; Rashidian A; Mirghazanfari M; Nezhadi A; Chamanara M; Mirjani R
Inflammopharmacology; 2021 Dec; 29(6):1807-1818. PubMed ID: 34780009
[TBL] [Abstract][Full Text] [Related]
58. The effect of the various doses of atorvastatin on renal tubular cells; an experimental study.
Nasri H; Hasanpour Z; Nematbakhsh M; Ahmadi A; Rafieian-Kopaei M
J Nephropathol; 2016 Jul; 5(3):111-5. PubMed ID: 27540539
[TBL] [Abstract][Full Text] [Related]
59. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
[TBL] [Abstract][Full Text] [Related]
60. Atorvastatin inhibits insulin synthesis by inhibiting the Ras/Raf/ERK/CREB pathway in INS-1 cells.
Sun H; Li Y; Sun B; Hou N; Yang J; Zheng M; Xu J; Wang J; Zhang Y; Zeng X; Shan C; Chang B; Chen L; Chang B
Medicine (Baltimore); 2016 Sep; 95(39):e4906. PubMed ID: 27684825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
